IL143579A0 - Erythropoietin derivatives for the treatment of cerebral ischemia - Google Patents

Erythropoietin derivatives for the treatment of cerebral ischemia

Info

Publication number
IL143579A0
IL143579A0 IL14357999A IL14357999A IL143579A0 IL 143579 A0 IL143579 A0 IL 143579A0 IL 14357999 A IL14357999 A IL 14357999A IL 14357999 A IL14357999 A IL 14357999A IL 143579 A0 IL143579 A0 IL 143579A0
Authority
IL
Israel
Prior art keywords
treatment
erythropoietin
cerebral
ischaemia
cerebral ischemia
Prior art date
Application number
IL14357999A
Other languages
English (en)
Inventor
Hannelore Ehrenreich
Christoph Gleiter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143579(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of IL143579A0 publication Critical patent/IL143579A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL14357999A 1998-12-14 1999-12-13 Erythropoietin derivatives for the treatment of cerebral ischemia IL143579A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PCT/EP1999/009864 WO2000035475A2 (de) 1998-12-14 1999-12-13 Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien

Publications (1)

Publication Number Publication Date
IL143579A0 true IL143579A0 (en) 2002-04-21

Family

ID=7891015

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14357999A IL143579A0 (en) 1998-12-14 1999-12-13 Erythropoietin derivatives for the treatment of cerebral ischemia
IL143579A IL143579A (en) 1998-12-14 2001-06-05 Erythropoietin history to treat local anemia of the brain

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143579A IL143579A (en) 1998-12-14 2001-06-05 Erythropoietin history to treat local anemia of the brain

Country Status (26)

Country Link
US (1) US7514072B1 (xx)
EP (1) EP1140139B2 (xx)
JP (2) JP4750947B2 (xx)
KR (1) KR100774827B1 (xx)
CN (1) CN1187085C (xx)
AT (1) ATE253932T1 (xx)
AU (1) AU766216C (xx)
BG (1) BG65417B1 (xx)
BR (1) BR9916197A (xx)
CA (1) CA2353553C (xx)
DE (2) DE19857609A1 (xx)
DK (1) DK1140139T4 (xx)
ES (1) ES2211218T5 (xx)
HK (1) HK1042655B (xx)
HU (1) HUP0104709A3 (xx)
ID (1) ID29107A (xx)
IL (2) IL143579A0 (xx)
MX (1) MXPA01005971A (xx)
NO (1) NO330079B1 (xx)
NZ (1) NZ541591A (xx)
PL (1) PL202483B1 (xx)
PT (1) PT1140139E (xx)
RO (1) RO121409B1 (xx)
RU (1) RU2242991C2 (xx)
WO (1) WO2000035475A2 (xx)
ZA (1) ZA200104626B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU784550B2 (en) * 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
EP1430114B1 (en) 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
CA2488497A1 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
BRPI0408829A (pt) * 2003-03-27 2006-04-04 Janssen Pharmaceutica Nv uso de eritropoietina em recuperação de acidente vascular cerebral
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
AU2006297041A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106986A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
WO2007142288A1 (ja) * 2006-06-07 2007-12-13 The University Of Tokushima エリスロポエチンを用いた虚血性疾患の治療
MY152789A (en) 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
ES2127458T3 (es) 1989-11-06 1999-04-16 Cell Genesys Inc Produccion de proteinas utilizando recombinacion homologa.
CA2071989C (en) 1989-12-22 1999-07-27 Scott C. Chappel Endogenous gene expression modification with regulatory element
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
WO1994025055A1 (en) 1993-04-29 1994-11-10 Abbott Laboratories Erythropoietin analog compositions and methods
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU784550B2 (en) 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
HUP0104709A2 (hu) 2002-04-29
ZA200104626B (en) 2002-09-06
CN1335776A (zh) 2002-02-13
RU2242991C2 (ru) 2004-12-27
ID29107A (id) 2001-07-26
MXPA01005971A (es) 2002-03-27
KR100774827B1 (ko) 2007-11-07
NO330079B1 (no) 2011-02-14
EP1140139B2 (de) 2009-03-18
IL143579A (en) 2007-10-31
HUP0104709A3 (en) 2002-05-28
DE59907752D1 (de) 2003-12-18
RO121409B1 (ro) 2007-05-30
WO2000035475A2 (de) 2000-06-22
KR20010082346A (ko) 2001-08-29
US7514072B1 (en) 2009-04-07
PL202483B1 (pl) 2009-06-30
ATE253932T1 (de) 2003-11-15
AU766216B2 (en) 2003-10-09
EP1140139B1 (de) 2003-11-12
BR9916197A (pt) 2001-09-04
DK1140139T3 (da) 2004-03-15
CA2353553A1 (en) 2000-06-22
DK1140139T4 (da) 2009-06-08
PL349335A1 (en) 2002-07-15
ES2211218T3 (es) 2004-07-01
EP1140139A2 (de) 2001-10-10
CA2353553C (en) 2011-05-17
DE19857609A1 (de) 2000-06-15
EP1140139B9 (de) 2004-03-31
ES2211218T5 (es) 2009-06-03
CN1187085C (zh) 2005-02-02
NZ541591A (en) 2007-08-31
PT1140139E (pt) 2004-04-30
NO20012896L (no) 2001-08-14
AU766216C (en) 2004-11-11
HK1042655A1 (en) 2002-08-23
WO2000035475A3 (de) 2000-10-19
BG65417B1 (bg) 2008-07-31
JP4750947B2 (ja) 2011-08-17
JP2002532432A (ja) 2002-10-02
AU2283100A (en) 2000-07-03
JP2011079860A (ja) 2011-04-21
NO20012896D0 (no) 2001-06-12
HK1042655B (zh) 2005-09-23
BG105575A (en) 2002-01-31

Similar Documents

Publication Publication Date Title
IL143579A0 (en) Erythropoietin derivatives for the treatment of cerebral ischemia
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
IL112572A0 (en) Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
EP1474158A4 (en) PREVENTING AND TREATING OXIDATIVE STRESS RELATED DISORDERS USING GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
WO2001021259A3 (en) Use and compositions for treating platelet-related disorders using anagrelide
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
EP2292226A3 (en) The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
CA2429793A1 (en) Interferon therapeutic effect enhancer
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
AU7230894A (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
MXPA04001951A (es) Coniosulfuros y sus derivados, procesos para prepararlos, y su uso como farmaceuticos.
TW200508229A (en) Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed